for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Celldex Therapeutics, Inc.

CLDX.OQ

Latest Trade

11.55USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

1.51

 - 

13.90

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
11.55
Open
--
Volume
--
3M AVG Volume
59.09
Today's High
--
Today's Low
--
52 Week High
13.90
52 Week Low
1.51
Shares Out (MIL)
35.93
Market Cap (MIL)
401.73
Forward P/E
-4.63
Dividend (Yield %)
--

Next Event

Q2 2020 Celldex Therapeutics Inc Earnings Release

Latest Developments

More

Adage Capital Partners L.P. Reports 5.01% Passive Stake In Celldex Technologies As Of July 14, 2020 - SEC Filing

Ikarian Capital Reports 7.1% Passive Stake In Celldex Therapeutics

Celldex Therapeutics Says Offering Of 13.4 Mln Common Shares Priced At $9.75 per Share

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Celldex Therapeutics, Inc.

Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients. Its Glembatumumab vedotin (also referred to as CDX-011) is meant for the treatment of metastatic melanoma. Its Varlilumab (also referred to as CDX-1127) is an immune modulating antibody. Its earlier stage drug candidates in clinical development include CDX-1401, which is a targeted immunotherapeutic aimed at antigen presenting cells (APC) for cancer indications and CDX-301, which is an immune cell mobilizing agent and dendritic cell growth factor. It includes a multi-faceted tumor-associated macrophage (TAM) program. The Company's pipeline also includes CDX-0158 and CDX-3379, which are humanized monoclonal antibodies.

Industry

Biotechnology & Drugs

Contact Info

53 Frontage Rd Ste 220

HAMPTON, NJ

08827-4034

United States

+1.908.2007500

http://www.celldextherapeutics.com

Executive Leadership

Karen Lipton Shoos

Independent Chairman of the Board

Anthony S. Marucci

President, Chief Executive Officer, Director

Sam Martin

Chief Financial Officer, Senior Vice President, Secretary

Tibor Keler

Executive Vice President and Chief Scientific Officer

Sarah Cavanaugh

Senior Vice President - Corporate Affairs and Administration

Key Stats

2.00 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2017

-10.800

2018

-14.480

2019

-3.510

2020(E)

-2.415
Price To Earnings (TTM)
--
Price To Sales (TTM)
82.39
Price To Book (MRQ)
2.37
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-39.02
Return on Equity (TTM)
-35.58

Latest News

Latest News

BRIEF-Ikarian Capital Reports 7.1% Passive Stake In Celldex Therapeutics

* IKARIAN CAPITAL LLC REPORTS 7.1% PASSIVE STAKE IN CELLDEX THERAPEUTICS INC AS OF JUNE 10 - SEC FILING Source: (https://bit.ly/3d9YpRX) Further company coverage:

BRIEF-Celldex Plans To Initiate Phase 1B Studies Of Cdx-0159 In Patients With Chronic Spontaneous Urticaria By Year End

* CELLDEX - PLANS TO INITIATE PHASE 1B STUDIES OF CDX-0159 IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA, CHRONIC INDUCIBLE URTICARIA BY YEAR END

BRIEF-Celldex Therapeutics Files Prospectus Supplement Related To Offering Of Common Stock Of Upto $18.3 Mln - SEC Filing

* CELLDEX THERAPEUTICS FILES PROSPECTUS SUPPLEMENT RELATED TO OFFERING OF COMMON STOCK OF UPTO $18.3 MILLION - SEC FILING Source text: https://bit.ly/2Y5Mu2Y Further company coverage:

BRIEF-Celldex Therapeutics Announces Proposed Public Offering Of Common Stock

* CELLDEX THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK Source text for Eikon: Further company coverage:

BRIEF-Celldex Announces Acceptance Of CDX-0159 Late-Breaking Poster Presentation With Voice Over At European Academy Of Allergy And Clinical Immunology (Eaaci) Annual Congress 2020

* CELLDEX ANNOUNCES ACCEPTANCE OF CDX-0159 LATE-BREAKING POSTER PRESENTATION WITH VOICE OVER AT EUROPEAN ACADEMY OF ALLERGY AND CLINICAL IMMUNOLOGY (EAACI) ANNUAL CONGRESS 2020 Source text for Eikon: Further company coverage:

BRIEF-Celldex Therapeutics Q4 Loss Per Share $0.64

* CELLDEX PROVIDES CORPORATE UPDATE AND REPORTS FOURTH QUARTER AND YEAR END 2019 RESULTS

BRIEF-Celldex Therapeutics To Receive $1.7 Mln Milestone Payment From Rockefeller Uni

* CELLDEX THERAPEUTICS ANNOUNCES $1.7 MILLION MILESTONE PAYMENT FROM ROCKEFELLER UNIVERSITY RELATED TO COLLABORATION ON HIV ANTIBODY PROGRAM Source text for Eikon: Further company coverage:

BRIEF-Novartis Receives Health Canada Approval Of Its Car-T Cell Therapy, Kymriah I

* NOVARTIS RECEIVES HEALTH CANADA APPROVAL OF ITS CAR-T CELL THERAPY, KYMRIAH™ (TISAGENLECLEUCEL)I

BRIEF-Celldex Therapeutics Reports Q1 Loss Per Share $0.84

* CELLDEX PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER 2018 RESULTS

BRIEF-Celldex Therapeutics Approves Workforce Reduction

* CELLDEX THERAPEUTICS INC - APPROVED A REDUCTION IN WORKFORCE TO REDUCE OPERATING COSTS AND BETTER ALIGN ITS WORKFORCE WITH NEEDS OF ITS BUSINESS

BRIEF-Celldex’S Metric Study In Metastatic Triple-Negative Breast Cancer Does Not Meet Primary Endpoint

* CELLDEX’S METRIC STUDY IN METASTATIC TRIPLE-NEGATIVE BREAST CANCER DOES NOT MEET PRIMARY ENDPOINT

BRIEF-Celldex Therapeutics Reports Q4 Loss Per Share $0.03

* CELLDEX PROVIDES CORPORATE UPDATE AND REPORTS FULL YEAR 2017 RESULTS

BRIEF-Celldex Therapeutics initiates phase 2 combination study of CDX-3379 and Cetuximab in head and neck squamous cell Carcinoma

* Celldex Therapeutics Inc initiates phase 2 combination study of CDX-3379 and Cetuximab in head and neck squamous cell Carcinoma Source text for Eikon: Further company coverage:

BRIEF-Celldex Therapeutics Q3 loss per share $0.20

* Q3 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S

BRIEF-Celldex announces completion of enrollment in phase 2b study of Glembatumumab Vedotin in triple negative breast cancer

* Celldex announces completion of enrollment in phase 2b study of Glembatumumab Vedotin in triple negative breast cancer

BRIEF-Celldex Therapeutics Q2 loss per share $0.23

* Celldex Therapeutics - Q2 revenue $3.8 million versus $1.4 million

BRIEF-Celldex Therapeutics Q2 loss per share $0.23

* Q2 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up